MDS-Bio1
Trial overview
Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS) and secondary disorders of haematopoiesis
Inclusion criteria
i) Patients with an abnormal blood count requiring investigation by blood and bone marrow sample.
ii) Patients known to have a blood disorder who are having a bone marrow sample taken as part of the assessment of that disorder.
Control subjects
Patients having elective orthopaedic surgery who have a normal blood count.
Exclusion criteria
i) Age < 18.
Controls
i) Age <18.
ii) On treatment likely to impair bone marrow function
iii) History of having had treatment likely to have impaired bone marrow function
Contact details
Other trials currently active for Myelodysplastic Syndromes
A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for
Acute Myeloid Leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5
A randomised, double blind, placebo controlled study evaluating the efficacy and safety of romiplostim treatment of thrombocytopenia in subjects with international prognostic scoring system (IPSS) low or intermediate-1 risk Myelodysplastic Syndrome (MDS) as measured by the number of clinically significant bleeding events.
The AML 17 trial has two distinct parts:
i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).
ii.For adults with acute promyelocytic leukaemia (APL).